Search / Trial NCT00000890

A Study to Evaluate the Effect of Anti-HIV Therapy on Lean Tissue (Muscle) in HIV-Positive Patients

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of December 05, 2024

Completed

Keywords

Hiv 1 Muscles Rna, Viral Body Composition Anti Hiv Agents Viral Load

ClinConnect Summary

Effective antiretroviral therapy, as measured by a decrease in HIV-1 RNA levels, may sustain or improve important components of body composition, perhaps through a decrease in the underlying pro-inflammatory activity and resting energy expenditure. Moderate weight gain has been reported to be associated with HAART. Meaningful increase in total body weight, however, may need to be comprised of augmentation of lean body mass (primarily muscle), since mortality in HIV and cancer wasting is associated with sizable decreases in lean body mass (LBM) and there is no evidence that increases in fat ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Patients may be eligible for this study if they:
  • Are enrolled in an adult AIDS clinical trial.
  • Are HIV-positive.
  • Have a viral load of at least 10,000 copies/ml.
  • Are expected to live at least 6 months.
  • Are at least 18 years old.
  • Exclusion Criteria
  • Patients will not be eligible for this study if they:
  • Have a history of diabetes requiring medication.
  • Have a history of heart disorders.
  • Have a fever, diarrhea, nausea, or a condition which makes it difficult to eat within the 14 days prior to study entry.
  • Have swelling due to any cause.
  • Are pregnant or breast-feeding.
  • Are receiving any therapy to increase your appetite or gain weight within 30 days prior to study entry.
  • Are receiving any therapy for a severe infection or medical illness within 14 days prior to study entry.
  • Are taking certain medications.

Trial Officials

C Shikuma

Study Chair

D Mildvan

Study Chair

F Sattler

Study Chair

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Los Angeles, California, United States

New York, New York, United States

New York, New York, United States

Columbus, Ohio, United States

Chicago, Illinois, United States

Seattle, Washington, United States

San Diego, California, United States

Chicago, Illinois, United States

Cleveland, Ohio, United States

San Francisco, California, United States

Stanford, California, United States

Washington, District Of Columbia, United States

Honolulu, Hawaii, United States

Boston, Massachusetts, United States

Philadelphia, Pennsylvania, United States

San Juan, , Puerto Rico

Boston, Massachusetts, United States

New Orleans, Louisiana, United States

New Orleans, Louisiana, United States

Atlanta, Georgia, United States

New York, New York, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials